Maternal and Child Health Research Center, Department of Obstetrics & Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Maternal and Child Health Research Center, Department of Obstetrics & Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Am J Obstet Gynecol MFM. 2019 May;1(2):101-111. doi: 10.1016/j.ajogmf.2019.06.003. Epub 2019 Jun 11.
The aim of the present systematic review was to investigate the efficacy and safety of cervical ripening for the combination of mechanical dilation and misoprostol administration compared with misoprostol alone by evaluating 2 primary outcomes: time to delivery and rate of cesarean delivery.
The Medline, EMBASE, and Web-of-Science electronic databases (from conception to end-of-search date December 31, 2018) were searched systematically. Randomized controlled trials that included patients with a singleton viable fetus who underwent induction of labor that required cervical ripening with an unfavorable cervix (Bishop ≤7) were eligible for inclusion.
Data were pooled with the use of the random effects and fixed effects model after the assessment for the presence of heterogeneity. Risk of bias for each included study was assessed based on the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions.
Eleven trials met the inclusion criteria and included a total of 922 and 947 subjects in the combination and misoprostol-only groups, respectively. There was no difference in the incidence of cesarean delivery between the 2 groups (relative risk, 0.95; 95% confidence interval, 0.80-1.13). The combination of mechanical dilation and misoprostol resulted in overall shorter time to delivery (mean difference, -3.65 hours; 95% confidence interval, 5.23 to -2.07), shorter time to vaginal delivery (mean difference, -4.53 hours; 95% confidence interval, -5.79 to -3.27), lower risk of neonatal intensive care unit admission (relative risk, 0.71; 95% confidence interval, 0.53-0.96), meconium-stained fluid (relative risk, 0.62; 95% confidence interval, 0.43-0.90), tachysystole with fetal heart trace changes (relative risk, 0.53; 95% confidence interval, 0.30-0.94), and terbutaline use (relative risk, 0.63; 95% confidence interval, 0.47-0.85) compared with the use of misoprostol alone. Risk of endometritis (relative risk, 1.07; 95% confidence interval, 0.43-2.61) and chorioamnionitis (relative risk, 1.58; 95% confidence interval, 0.88-2.84) was comparable between the 2 groups.
The combination of mechanical cervical dilation with misoprostol for cervical ripening is associated with a shorter time to delivery, a similar rate of cesarean delivery, and a lower incidence of neonatal intensive care unit admission compared with the use of misoprostol alone.
本系统评价的目的是通过评估 2 个主要结局指标,即分娩时间和剖宫产率,来调查机械扩张联合米索前列醇与单独使用米索前列醇进行宫颈成熟的疗效和安全性。
系统检索了 Medline、EMBASE 和 Web-of-Science 电子数据库(从概念到 2018 年 12 月 31 日搜索结束日期)。纳入标准为:接受需要宫颈成熟的引产且宫颈条件不佳(Bishop≤7)的单胎活胎患者的随机对照试验。
在评估异质性存在的情况下,使用随机效应和固定效应模型对数据进行汇总。根据《 Cochrane 系统评价干预手册》中列出的标准评估纳入研究的偏倚风险。
11 项试验符合纳入标准,机械扩张联合米索前列醇组和单独使用米索前列醇组分别纳入 922 例和 947 例患者。两组剖宫产率无差异(相对风险,0.95;95%置信区间,0.80-1.13)。机械扩张联合米索前列醇组总体分娩时间更短(平均差,-3.65 小时;95%置信区间,5.23 至-2.07),阴道分娩时间更短(平均差,-4.53 小时;95%置信区间,-5.79 至-3.27),新生儿重症监护病房入住率更低(相对风险,0.71;95%置信区间,0.53-0.96),胎粪污染羊水发生率更低(相对风险,0.62;95%置信区间,0.43-0.90),胎心变化的宫缩过速发生率更低(相对风险,0.53;95%置信区间,0.30-0.94),以及使用特布他林的比例更低(相对风险,0.63;95%置信区间,0.47-0.85),而与单独使用米索前列醇相比。两组子宫内膜炎(相对风险,1.07;95%置信区间,0.43-2.61)和绒毛膜羊膜炎(相对风险,1.58;95%置信区间,0.88-2.84)的风险无差异。
与单独使用米索前列醇相比,机械宫颈扩张联合米索前列醇进行宫颈成熟与分娩时间更短、剖宫产率相似以及新生儿重症监护病房入住率更低相关。